Oct 25 (Reuters) – Johnson & Johnson: * JOHNSON & JOHNSON REPORTS 75% TUMOR RESPONSE RATE IN ADVANCED PROSTATE CANCER WITH JNJ-6143, A FIRST-IN-CLASS RIPTAC™ MOLECULE Further company coverage:
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
ADVISORY – SPORTS DAILY OUTLOOK SUNDAY OCTOBER 25, 2026
SPORTS - DAILY OUTLOOK - SUNDAY OCTOBER 25, 2026 . EXPECTED: . 2913-MOTOR-MOTOGP-AUSTRALIA/ Australian Grand…
Oct 25 (OPTA) - Summaries for the MLS on Saturday (start times are EST) Montréal…
Employees group warns of major Swiss job losses if UBS relocates, newspaper says
ZURICH, Oct 25 (Reuters) - As many as 12,000 UBS jobs in Switzerland could be…
